Cellular Fingerprint Assay - A Perfect Tool for Early Drug Discovery

Speaker
  • CSO, Immunologix
    Biography
      Paul brings more than 20 years of senior scientific leadership in designing, building, and validating immunoassays used to measure clinical biomarkers, therapeutic targets, and immune responses against biologics. He is responsible for the scientific oversight and integrity of all the bioanalytical work performed at Immunologix Laboratories and provides executive oversight to ensure the work is in conducted in accordance with regulatory requirements and guidelines. Dr. Rhyne is a well-recognized industry expert that has experience in multiple biotechnology, pharmaceutical, and contract research organizations. He has published numerous publications in peer reviewed journals, contributed to many key industry white papers, and is an active member of the American Association of Pharmaceutical Scientists.

    Abstract

    Biologic based therapeutics are used for treatment of many diseases and represent the most advanced therapies available. These drugs often generate immune responses in patients that may impact drug efficacy and adversely affect patient safety. Regulatory agencies responsible for drug approval recommend an assessment of anti-drug immune responses including a screening assay to detect the presence of anti-drug antibodies (ADA), titer, assessment of drug neutralizing activity, and classification of ADA responses with respect to antibody class and subclass. The industry uses singleplex assays to detect and characterize ADA responses in a tiered sequential manner. This presentation will introduce the concepts of Immunogenicity and share a novel multiplexed based approach to detect and characterize ADA responses.

    We selected Humira, a human IgG1 antibody that binds to TNFa as the biologic drug for this study which has been shown to induce ADA responses. Biotinylated Humira was used to capture and isolate ADA from clinical samples using streptavidin coated plates. This also removed non-specific antibodies and other matrix components from the purified ADA preparation. The ADA were subsequently mixed with Luminex bead sets each coupled to an Fc specific anti-human Ig class or subclass to delineate the different classes and subclasses from each other. These included human IgG1, IgG2, IgG3, IgG4, IgM, IgA, and IgE. The beads were washed and incubated with biotinylated Humira to detect drug specific ADA captured on each bead set. Streptavidin-phycoerythrin was added followed by analysis of the bead sets in a Luminex Flexmap-3D instrument. The median fluorescence intensity (MFI) of >50 beads per set was calculated and used in the final data analysis.

    The data show that each isotype specific bead set had good specificity for the respective isotype. The detection of ADA in samples was based on a statistically derived cut point based on a set of 50 drug-naïve samples analyzed in the assay 6 times across several days. This cut point was set so that 95% of drug naïve samples fall below the cut point and samples with drug specific antibodies present would generate a signal above the cut point. The cut point was set to yield a 5% false positive rate to ensure all samples with ADA would be detected. A separate cut point was calculated for each specific antibody class or subclass. Clinical samples from psoriasis patients and other autoimmune disease patients were analyzed for the presence of ADA. The results show the presence of ADA and a mixture of different isotypes present. The sensitivity of the assay was determined to be less than 50 ng/ml using a human anti-Humira antibody as a positive control. The presentation will also show data from clinical samples with respect to the presence of ADA and the respective isotypes present.

    The multiplexed approach described here demonstrate an advantage over single assay approaches with respect to minimizing clinical sample freeze thaws, cost and labor, while providing a robust and reliable method for ADA evaluation. This method yielded results that were comparable to the FDA guidelines for assessment of Immunogenicity.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    MAY 12, 2020 9:00 AM PDT
    C.E. CREDITS
    MAY 12, 2020 9:00 AM PDT
    NEW DATE: Date: May 12, 2020 Time: 9:00am PDT, 12:00pm EDT...
    Loading Comments...
    Show Resources